Global metastatic cancer treatment market to grow at 7.3 % during 2019-2027

The global metastatic cancer treatment market size is set to grow at a compound annual growth rate of 7.3 per cent from $63.03 billion in 2019 to $111.16 billion in 2027. This growth is fuelled by several key factors such as innovative therapies like molecular targeted therapy and immunotherapy, along with combination regimens, which are transforming the anti-cancer drug market by improving treatment efficacy and reducing toxicity. Increased R&D investment and health system initiatives, such as promoting minimally invasive treatments and medical tourism in regions like India and Japan, are also driving market growth, says GlobalData.

NovoCure, a US-based oncology company, has recently received FDA approval for its wearable device designed to treat metastatic cancer. The device, which utilizes NovoCure’s proprietary Tumor Treating Fields (TTFields) technology, offers a non-invasive therapeutic approach to patients with advanced metastatic cancer, providing a new avenue of treatment for those who have exhausted conventional options.

The newly approved device targets solid tumour growth by delivering electric fields to disrupt the division of cancer cells, reducing tumour progression. It has demonstrated significant efficacy in clinical trials, particularly in metastatic cancers that have been resistant to other forms of therapy.

Graysen Vigneux, Medical Analyst, GlobalData, comments, “This approval marks a milestone for metastatic cancer patients, offering a new treatment modality that could significantly enhance survival rates. The ability to deliver treatment continuously through a wearable device is a game changer in cancer care, as it allows patients to undergo therapy while maintaining their daily routines.”

The approval comes after promising results from NovoCure’s phase III clinical trials, which showed a meaningful increase in progression-free survival and overall survival rates for patients using the TTFields device in combination with standard therapies. Patients using the wearable device experienced fewer side effects compared to traditional cancer treatments like chemotherapy and radiation, marking an advancement in patient quality of life.

Vigneux concludes, “Patients are now able to receive a non-invasive treatment that directly targets cancer cells while sparing healthy tissue. This innovation provides real hope for those battling metastatic cancer, especially when other therapies have failed.”

NovoCure looks to make the device available to patients in the US immediately and will work with oncologists and healthcare providers to integrate the technology into the existing treatment plans for metastatic cancer.

Edits made by EH News Bureau